11 results match your criteria: "Police Medical Centre of Thessaloniki[Affiliation]"
Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH.
Endocrine
May 2022
Department of Endocrinology, Police Medical Centre of Thessaloniki, Thessaloniki, Greece.
Article Synopsis
- The study investigates the link between lipoprotein(a) [Lp(a)] levels and the prevalence of atherosclerotic cardiovascular disease (ASCVD) in adults with familial hypercholesterolemia (FH).
- In a sample of 541 patients, those with higher Lp(a) concentrations showed a notable increase in ASCVD prevalence, with rates rising from 9.4% in the lowest tertile to 20.6% in the highest.
- The findings suggest that elevated Lp(a) levels are an important risk factor for ASCVD in individuals with FH, emphasizing the need for monitoring and addressing Lp(a) in this population.
Prevalence of Non-coronary Heart Disease in Patients with Familial Hypercholesterolemia: An Analysis from the HELLAS-FH.
Curr Pharm Des
October 2021
Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.
Aims: Despite the established link between familial hypercholesterolemia (FH) and increased risk of coronary heart disease (CHD), its association with other common atherosclerotic and metabolic diseases has not been extensively studied. The aim of this study was to report the prevalence of peripheral arterial disease (PAD) [i.e.
View Article and Find Full Text PDFVascular surgical procedures in patients with familial hypercholesterolaemia: is it too late?
Curr Med Res Opin
August 2020
Department of Clinical Biochemistry and Department of Surgery, Royal Free Hospital Campus, University College Medical School, University College London, London, UK.
Non-coronary atherosclerotic cardiovascular disease in patients with familial hypercholesterolaemia.
Curr Med Res Opin
May 2020
Department of Clinical Biochemistry and Department of Surgery, Royal Free Hospital Campus, University College Medical School, University College London, London, UK.
Familial hypercholesterolaemia (FH) is a common autosomal dominant inherited disease, affecting 1 in 200-500 individuals worldwide. FH is characterized by elevated circulating low-density lipoprotein cholesterol (LDL-C) concentrations. Its association with increased risk of coronary heart disease (CHD) (>10-fold, compared with patients without FH) is well documented.
View Article and Find Full Text PDFManagement of dyslipidaemias in the elderly population-A narrative review.
Maturitas
June 2019
Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
The impact of dyslipidaemias on the risk of cardiovascular disease (CVD) is well documented. However, it is often under-estimated and, sometimes, suboptimally managed in the elderly population. The prevalence of dyslipidaemias seems to decline from the 7 decade of life in both genders.
View Article and Find Full Text PDFShould we Consider Lipoprotein (a) in Cardiovascular Disease Risk Assessment in Patients with Familial Hypercholesterolaemia?
Curr Pharm Des
November 2019
National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, London SW3 6NP, United Kingdom.
Background: Familial hypercholesterolaemia (FH) is a genetically determined lipid disorder, affecting 1 per 200-500 individuals in the general population. It is significantly and independently associated with an increased risk of Cardiovascular Disease (CVD), although it remains still an underrecognized and undertreated disease. Lipoprotein (a) [Lp(a)] is a low-density-lipoprotein (LDL)-like molecule, containing an additional protein, apolipoprotein (a).
View Article and Find Full Text PDFBisphosphonate drug holidays--when, why and for how long?
Climacteric
September 2016
b National Heart & Lung Institute, Imperial College London, Royal Brompton & Harefield NHS Foundation Trust , London , UK.
Bisphosphonates are first-line agents used for the treatment of osteoporosis in postmenopausal women and men. Although their efficacy in the reduction of vertebral, non-vertebral and hip fracture risk has been established, some concerns have arisen associated with their long-term use. These include osteonecrosis of the jaw and atypical (subtrochanteric and femoral shaft) fractures.
View Article and Find Full Text PDFCompliance with osteoporosis medications - an underestimated determinant of anti-fracture efficacy.
Curr Med Res Opin
May 2015
Division of Endocrinology Police Medical Centre of Thessaloniki, Sarantaporou 10, Thessaloniki, 54 640 , Greece.
The interplay between TSH and lipids. what should clinicians know?
Curr Vasc Pharmacol
November 2015
Division of Endocrinology, Police Medical Centre of Thessaloniki Sarantaporou 10, Thessaloniki, 54 640 Greece.
Monitoring the efficacy of once-weekly teriparatide. Are bone turnover markers useful in predicting fracture risk?
Curr Med Res Opin
June 2014
Division of Endocrinology, Police Medical Centre of Thessaloniki, Sarantaporou 10, Thessaloniki, 54 640 , Greece.
Should we stop prescribing pioglitazone?
Br J Clin Pharmacol
August 2014
Division of Endocrinology, Police Medical Centre of Thessaloniki, Thessaloniki, Greece.